full comment requir non-u analyst conflict disclosur
pleas click link
adcom brief doc show agenc skeptic oct meet
moor less
expect line street out-year ebitda high lower forecast target
recap model updat
sept-qtr preview like revenu upsid nand price
real competitor
tripl confer kol dinner bring kra insight promis concern
track bit estim
post in-lin result surpris guidanc affirm
fda issu safeti commun afx devic
result exist oper estim cobr panama progress well
result strong real estat result off-set weak timberland
upcom import updat remain cautiou risk anoth reset
preview remain buyer year-end
result mix
catch manag
price prior day market close estimate unless otherwis note
confer takeaway thought set-up teva
take print model updat
choppi expect pocket worsen
gener pharma thought near-
gm uaw reach deal end
takeaway money
 of daili summari
earn tomorrow
trend fundament review
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site
profit remain strong bank stock still own
focu legaci vs new
pe buyer sentiment remain bearish ampl suppli earn season begin
adu realli approv clinic statist deep dive confer call
valu usd unless otherwis note
adcom brief doc show agenc skeptic oct meet
agrx report coincid releas brief doc ahead
fda advisori committe meet twirla though bind outcom
adcom go increasingli import twirla approv opportun
pdufa view push launch made model chang
price target expect stock highli volatil adcom pdufa
adcom question unsurprisingli focus safety/efficaci howev brief
doc reflect high level skeptic includ around agrx label propos
fda appear agre compani propos limit use lou
women higher bmi compani point higher pearl index
phase secur trial partli skew real world enrol
trial includ obes women pearl valu higher propos
lou includ cautiou languag around reduc efficaci ie higher pearl
popul sought mitig issu howev brief doc
indic sever concern agenc approach note lou
typic includ data sub-popul insuffici warrant
definit statement case clear product
efficaci women unaccept also specifi
ortho evra/xulan contain similar lou data ortho registr trial
base find smaller portion overal popul
agenc also believ twirla data obes subject clinic
meaning definit
post solid result revenu upsid cloud secur
y/i ex-fx cdn ebitda beat continu focu
oper effici akam guidanc modestli rais
revenu tighten ebitda tweak estim price target
maintain sector perform particip novemb
solid bracket result revenu rbc/street est
upsid cloud secur strong growth
across video softwar game download traffic ebitda
rbc/street driven part lower expect spend across
 revenu ebitda guid bracket street though akam
ebitda guid larg unchang partial due higher compens
acquisit market cost fundament trend solid ex-
fx revenu growth deceler y/i ebitda margin bp
y/i reiter goal non-gaap op margin
valu usd unless otherwis note
valu usd unless otherwis note
market data usd financi data eur
moor less
despit tangibl sign improv off-shore drill activ price
pace recoveri slower initi anticip dynam push
timelin becom posit remain sector perform
reduc ebitda estim
associ ep prior chang
primari reflect revenu oper cost adjust ebitda
estim increas reflect better-than-expect
new price target base multipl previous
ebitda previous chang multipl
reflect prospect slower ebitda recoveri trough level
even close glpg partner morphosi announc
follow failur mab ph ii iguana atop dermat
studi interim analysi studi drug lead indic
discontinu somewhat surpris believ larger question
around program surround differenti efficaci potenti
though see increment neg remov
impact valuat continu see balanc reward/risk filgotinib
commerci opportun potenti rest glpg pipelin
even close glpg partner morphosi announc
follow failur mab ph ii iguana atop
dermat studi interim analysi studi drug lead
indic discontinu
pt continu see balanc reward/risk
market data usd financi data eur
valu usd unless otherwis note
morn mru provid new data bispecif antibodi
breast cancer program drug de-priorit
hint grow enthusiasm mutation-specif
trial compani present initi promis signal activ
fusion posit solid tumor formal shift away
broader breast gastric indic signific reset program
develop rel earli potenti unknown could
help facilit rapid execut path mru potenti increas
investor enthusiasm adjust price target model updat
though continu see opportun signific share appreci
potenti best-in-class bispecif platform expand suit asset gain
attent addit upcom data readout
morn mru provid new data bispecif antibodi
breast cancer program drug de-priorit
mru express grow enthusiasm mutation-specif trial
compani present initi promis signal activ fusion
believ new direct could provid potenti rapid path
develop increas investor enthusiasm note mani
unknown adjust target model updat
maintain sector perform rate primarili reflect caution toward us/ca
eu truck market littl suggest quick snap-back wide expect
downturn view
updat model reflect report oct upsid
margin off-set lower expect deliveri rel forecast
forward debat includ build rate adjust enough
balanc next year see sustain acceler monthli heavy-
duti truck order whether elev industri inventori new class truck
overhang rebound target decrement
margin framework achiev soften industri use truck metric
continu overhang cycl rebound
rais captur upsid ep
includ lower rev price target
expect line street out-year ebitda high lower forecast
valu usd unless otherwis note
valu usd unless otherwis note
approach back attendance/present gener
supplier confer revisit model forecast
line street think realist littl surpris like
quarter believ street out-year forecast high lower
estim lower target
lower ebitda billion street
billion billion chang billion two
primari driver temper gross margin assumpt slightli
face copaxon eros limit brand support ie
ajovi street reflect modest annual improv
offset slightli higher revenu forecast ii revisit
oper expens assumpt follow conclus billion overal
cost save street number still reflect cost cut continu
annual forecast concern unrealist
million street new forecast assum revenu
growth spend move modestli higher though still reflect
aggress cost contain final rais interest rate assumpt
given state refinanc need billion higher level
push ep lower compar street
recap model updat
t-mobil post solid result margin slight servic revenu upsid
offset lower-than-expect equip revenu drive healthi
ebitda beat manag increas guidanc brand postpaid net
add ebitda capital-expenditure maintain outlook expect continu
subscrib momentum churn improv back greater enterprise/
smb/public-sector penetr network improv retail expans
rais price target
summari total revenu grew y/i reflect
servic revenu y/i equip revenu y/i servic
revenu exceed rbc/consensu estim equip
revenu miss drive downsid total revenu
howev ebitda margin bp rbc/consensu
drive ebitda growth rbc/consensu
guidanc manag increas target follow brand
postpaid net add ebitda
includ leas revenu capital-expenditure
exclud capit interest vs previous net
cash oper activ outlook
unchang improv net cash oper activ
off-set higher expect capital-expenditure manag expect brand postpaid
phone arpu declin vs prior rang
revis estim price target revenu declin
lower equip revenu estim ebitda estim
larg unchang price target increas roll-
forward impact dcf model coupl slightli higher out-year ebitda/
valu usd unless otherwis note
continu see sequenti improv perform oper
earn growth next year off-set one-tim item tweak estim slightli
lower pt
consist management guidanc result reflect sequenti
effort off-set lower pharmaci reimburs challeng uk
oper environ gain traction enabl bounc back
larg result unfavor comparison vs reduc bonus
higher tax rate management expect adj ep flat yoy
oper earn growth top-line growth
given known headwind step next year expect
continu improv script retail trend bake guidanc
would anticip healthi amount skeptic investor
compani abl deliv
sept-qtr preview like revenu upsid nand price
head sept-qtr print modestli increas estim reflect
higher end origin guidanc notabl full year estim move
slightli think near-term upsid limit begin ramp
materi quarter work past bottom nand price
valu usd unless otherwis note
take-away sept-qtr move higher end guid
rang anticip better expect result nand busi
potenti upsid disk drive hyperscal spend improv
importantli set expect modest beat given nand
price environ recent improv posit western
digit manag team abil capit improv
environ maintain lower opex structur net net rais
price target increas estim modestli keep
pe multipl north
real competitor
attend aacr-nci-eortc tripl confer boston initi
data mrtx kra inhibitor present suggest safety/
efficaci profil appear par ns mrtx press
releas data detail highli impress orr nsclc
patient highest bid dose vs ns
orr nsclc orr howev present
valu usd unless otherwis note
data tripl meet disclos data slightli less entic
nsclc respond unconfirm avail scan data cutoff
oct cutoff see data support viabl
product howev see data earli rigor cross-trial comparison
ns well ahead develop see exhibit
waterfal swimmer plot confer conserv model
amgn launch achiev peak risk adjust po
continu see peak revenu risk assumpt
highli conserv howev note market grow increasingli
competit current enjoy lead nearest
competitor clear efficaci leader yet determin
tripl confer kol dinner bring kra insight promis
host live client dinner boston conjunct aacr-nci-
eortc tripl confer featur two key opinion leader respect
expert within field pulmonari oncolog early-stag target
oncolog clinic experi administ
inhibitor kol larg balanc amgn class-
leader mrtx saw initi data present
yesterday confer neither promin expert will declar
either agent clearli superior data-to-d link
real competitor amgn cancer came
away dinner similar perspect though note sever nuanc
emerg dinner help shape understand
competit landscap relat enrol select pk differ
overal trial strategi safeti characterist
valu usd unless otherwis note
valu usd unless otherwis note
track bit estim
modestli ahead expect brown brown report ep
vs better estim
consensu estim slight posit varianc estim due
better-than-anticip organ growth tax rate partli off-set softer-
organ growth outpac estim total commiss fee revenu
jump million estim organ revenu
estim three four unit gener
margin pressur brown report ebitdac margin weaken
basi point estim lower margin reflect
dilut hay acquisit point higher expens
point partli off-set gain dispos
first view/confer call topic thought mix quarter
organ growth decent whole soft patch busi
bit surpris magnitud margin weak quarter
especi see nice margin improv call
valu usd unless otherwis note
valu usd unless otherwis note
expect key topic focu may includ addit color margin
 price market environ thought trend
post in-lin result surpris guidanc affirm
take-away post solid essenti line expect
weve come expect top-line growth reflect steadi develop activ
strong ss growth segment non-organ irf growth also reflect
consolid segment yuma az jv irf ebitda dip optic due
insur recoveri book last year quarter relat hurrican
margin contract includ known item includ drag alacar
acquisit train cost relat tool transit irf
segment claim denial acceler expect due tpe review
expect much updat pdgm ahead home health final rule
fda issu safeti commun afx devic
fda issu safeti commun risk type endoleak
use elgx afx endovascular aaa graft system yesterday fda
announc evalu new inform risk type endoleak
elgx afx graft afx-strata afx-durapli use
treat aaa previous elgx fda issu field safeti notic afx-
strata howev fda elev new data three devic
although abstract dataset import consid believ may
limit requir evalu initi concern
data includ small number patient dataset use graft
patient second result compar endovascular graft
system third result distinguish gener graft strata
vs durapli saw leak final result indic instal graft
use accord afx ifu howev evalu suggest
particular caus endo-leak compar
competit product may caus uncertainli elgx financi
step biggest question investor ask latest fda
announc impact elgx effort stabil afx busi elgx report
earn novemb market close manag
revenu guidanc includ revenu least rbce vs fce
result exist oper estim cobr panama progress
view could see weak result oper exclud
cobr panama estim lower recoveri kansanshi
temporari ball mill failur la cruce eps/ebitda close estim
includ one month sale cobr panama may
directli compar consensu estim announc last week cobr
panama continu progress well commerci product declar
septemb fm made chang product oper cost
capital-expenditure guidanc howev remov guidanc note
would updat februari fm recogn financ charg
discount vat receiv zambia base expect time payment
stand
market data cad financi data usd dividend paid
valu usd unless otherwis note
result strong real estat result off-set weak
result exceed expect larg due better-than-expect
result estat wood product partial off-set weaker
timberland result adjust ebitdda forecast
consensu higher-than-expect result
primarili driven estat sell rural acr expect wood
timberlandsadjust ebitdda wasbelow
forecastin south lower-than-expect shipment price
off-set better-than-expect margin result southern timberland
ebitdda forecast north shipment
price margin modestli lower-than-expect result lower-
than-expect northern resourc ebitdda vs rbce
wood product adjust ebitdda forecast
stronger-than-expect shipment mmfbm vs rbce mmfbm
price vs rbce reason segment
estat ebitdda ahead estim potlatch
sold rural acr doubl manag expect well
acr forecast averag price vs
compani also close commerci real estat transact chenal valley
follow pti cystic fibrosi summit morn continu see potenti
activ ph ii readout expect addit detail
summit -- like focu ex-u geographi patient feedback desir
treatment option -- support potenti nich role
pti asset success reach market
pti appear focus ex-u geographi access still
kol patient feedback highlight need new treatment desir
look beyond though believ latter would take evolut
approach studi
valu usd unless otherwis note
valu usd unless otherwis note
in-lin result across metric wast connect report
adj ebitda y/i come in-lin prior guidanc
consensu organ growth way core
price volum growth off-set
recycl fx headwind importantli adj
quarter revenu came estim put
gener ytd posit compani well
meet exceed full year adj guidanc
visibl manag note acquisit activ
alreadi averag pace mid-year report juli
dialogu remain high sever potenti transact could close
later year earli next key similar solid wast organ
growth acquisit contribut alreadi place wcn posit
deliv mid high singl digit revenu growth y/i
addit acquisit recycl price improv provid
upcom import updat remain cautiou risk anoth reset
report next thur new leadership given last quarter
announc manag chang trend remain challeng limit
launch activ size per prior note expect target
revisit cut call volum heavi sinc move ebitda street
lower ahead print drill swing factor
quarter import first current guidanc set prior
manag chairman paul bisaro ceo rob stewart departur announc
re-affirmed call expect current manag
provid updat left year second new launch
activ limit busi trend remain challeng impli
us pressur busi like greater previous anticip
third leverag street ebitda million guidanc million
million impli move toward million would push
valu usd unless otherwis note
valu usd unless otherwis note
anoth half turn reflect hit potenti opioid
settlement even hold ebitda flat impli full
year number million would still forecast sever gener
segment swing factor think note concern sole
gener busi see brand trend rel stabl
preview remain buyer year-end
head result importantli ph lupu nephriti ln
data readout aurora trial like setup auph share notwithstand
binari natur event comfort risk/reward current
level given manag team similar aurora success ph
ii trial option dri eye program
revisit thesi chang fundament pictur anyth
compani arguabl better posit time
initi februari share essenti flat sinc time recal
posit view continu base voclosporin vc posit
potenti first fda/ema approv therapi lupu nephriti ln ln
treat off-label case drastic improv patient outcom
yet seen believ vc becom stapl new multi-target
treatment approach consider benefit versu current method
ph aurora trial run essenti way success ph
ii aura-lv studi final believ manag expertis lupu nephriti
also benefici take vc fda approv commerci
sinc launch compani continu execut earli enrol
start address key risk factor vc ip extens advanc dri eye
program thu remain buyer auph head end year
note event ph ln trial fail would expect share
declin normal current level
mimecast report result overal expect solid quarter
constant currenc vs expect continu like opportun
numer driver addit features/product traction up-market solid
result indic solid demand email secur market
maintain op pt
need know base check expect slight upsid cc consensu
revenue/ep expect mimecast report
result sinc result mime vs
ytd share vs investor sentiment
mix inter-quart worri surround compani uk
exposur announc ed jen departur year-end
outsid fx headwind highlight see event
direct impact constant currenc result continu think compani
perform well numer driver includ increas enterpris
valu usd unless otherwis note
valu usd unless otherwis note
penetr continu up-sel opportun convers current
penetr deal see higher servic attach rate
increas legaci share-shift opportun recent market chang
cross-sel maintain op pt monitor product news
compani cyber resili summit start today
base intra-quart data point model sensit analysi believ
street revenu ebitda estim quarter reason
greater chanc upsid vs downsid varianc given current busi
momentum would expect manag least reiter full-year guidanc
believ street revenu growth assumpt q/q growth
ebitda estim ballpark reason
pinterest report result thursday octob look
revenu adjust ebitda vs street
revenu estim street ebitda estim
note estim exceed street revenu ebitda
look net new monthli activ user in-lin street
note street expect mau risen sinc earli octob
specif estim pinterest add user
report mix ep result revenu beat ep miss
stori revenu margin trend consist organ revenu
growth oper margin bp y/i last qrt less
result number gross revenu came slightli ahead
rbc/street driven mobil search youtub cloud gaap op incom
came approx street would beat street
ex french legal settlement ooh la la notabl oi came
loss due impact mark invest loss incl recent
public compani slack fundi consist
organ revenu growth in-lin vs match
averag gaap op margin fell modest bp y/i adjust french
legal settlement prior qtr
valu usd unless otherwis note
valu usd unless otherwis note
high share repo bring share repo ytd
longer chump chang cash equiv balanc sheet
maintain outperform believ revenu growth year
scale extraordinarili impress arguabl sustain
remain global advertising/market spend base
extens survey work dont see evid chang market view
googl believ compani invest innov
comput help set compani year premium growth profit
valuat remain reason price-to-earnings ebitda view
result mix
low expect result mix primari concern
billings/def revenu weak focu like remain
continu soft billings/def revenu implic financi
model season stronger could impli outlook
maintain sector perform pt
need know lead metric trail expect defer
revenu q/q bill y/i
transform annuiti product tougher compar certainli
influenc believ mani investor still grappl could
view continu soft lead metric potenti implic
evolv financi model beyond result line
revenue/ep vs consensu in-lin product
licens revenu though product licens revenu
ninth straight quarter y/i secur subscript revenu durabl
y/i averag last seven quarter vs consensu
sens stock like paus front
initi guidanc expect next quarter think investor
like debat growth rate level invest maintain/dr share
growth appear handcuf industry-high margin st
 lt cash might see acquisit point refer largest
 deal pointsec
catch manag
recent investor enlc enlc clearli pressur rig
movement stack lack transpar enlc ok
volum think enlc option off-set ok declin consid
sell-off weight downsid scenario think enlc suffici
flexibl navig cycl better commod backdrop
stack lower ga ngl price produc shift away stack
run stack rig market expect one
enlc stack-focus custom without luxuri shift
activ still littl visibl rig activ across enlc stack footprint
earn think enlc could provid color potenti stack
well connect view current valuat impli y/i ok volum
declin enlc system get conserv volum
updat estim reflect y/i declin ok volum
think enlc flexibl navig cycl maintain rate
pt commod outlook suggest improv stack econom
keep mid-rang thesi intact regardless downsid scenario enlc
like compel better crystal manag balanc sheet dividend
cost cycl
valu usd unless otherwis note
valu usd unless otherwis note
take print model updat
see vfc strong brand portfolio key asset navig retail volatil given
divers revenu base across categori channel geographi
earn see thesi unchang result support
compani baselin tsr profil posit risk/reward current level
consist earn compound stori tweak ep pt stay
expect high head print bear
rare ep miss top van deceler remain encourag van
could outperform guidanc hsd said market exit plan
updat van outlook like still room realist less vs
ytd contrast encourag north face boost
cc outlook product/demand creation effort take hold tnf build
momentum ultim allow room van softer land
affirm ep guid absorb increment fx tariff
hong kong headwind emb rais van tnf margin
gm gain expect slight fy sg leverag
septemb analyst day laid plan top line compound-annual-growth-rate
least ep big four brand run cc ytd
believ long-term thesi tsr profil remain firmli tact
kick earn read-across includ posit us
consum holiday healthi inventori retail partner uk traffic
decel callout rl tougher hong kong callout strength
elsewher china tnf rais outlook bode better outerwear
tweak estim ep move
target remain appli updat
valu usd unless otherwis note
valu usd unless otherwis note
follow trend sever announc transact rarx aldr achn
space near-term action drug action seem less like perhap
surpris see total si decreas slightli across space
align view increasingli favor sentiment attract
valuat stabil outflow potenti increas bd continu make
sector attract near-to-medium term
gener pharma thought near-term posit
confer takeaway thought set-up teva
return gener industri confer buy/sell-sid
present caught industri contact meet coincid
pick-up investor focu around set-up upcom earn
season kick thur remaind report next week overal tone
repres on-going challeng reflect industri
litig sieg opioid price fix industri dynam continu present
challeng buyer increasingli split suppli relationship aggress
rebat name look see select pressur out-
year ebitda teva expect opioid headlin continu
drive stock perform teva op-rat stock
realiti close still month away investor
seemingli put stock show-m box larger
manufactur still trade ebitda rang would focus
downsid revis out-year ebitda risk stock downsid
given leverage/cash flow focu thought set-up order convict
also lower teva target separ note link
mine share last week follow commod continu
move monday octob trade deal optim expect
rate cut week presid trump said monday expect
sign signific part trade deal china ahead schedul reuter
broader market also ralli trade optim expect
would announc anoth interest rate cut later week nickel
last week today fall despit
report reuter indonesian miner decid stop export nickel
today versu plan ban start januari previous ban
plan move earli septemb see chart
week nickel exchang inventori fallen sharpli past month
anoth last week copper last week
lb exchang inventori decreas last week net short posit
specul copper decreas last week contract
zinc inventori decreas last week zinc price increas
mine share trade discount forward curv
share trade premium versu discount one
gm uaw reach deal end strike carload note
valu cad unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
gm employe vote favor new four-year labor agreement end
long strike neg affect auto suppli chain carload
class railroad note affect
strike motor vehicl part carload
respect octob base estim automot account
revenu railroad also relationship gm carload
less affect automot repres smaller proport revenu
addit cp told us volum materi affect
strike
canadian class carload due lower metal ore metal
well decreas intermod carload
us class volum lower due decreas intermod coal carload
takeaway money
takeaway first two day money arguabl one
largest fintech/pay confer world attend larg
number session across mani differ theme believ global
need scale remain top mind
cross-bord payment digital-first merchant payment
choppi expect pocket worsen
short-cycl industri pressur trade war casualti investor
appropri brace mix earn result quarter
way earn season play far appear us
investor still posit soft land slowdown point
doubt definit direct macro
compani report bia stay defens posit
expect earn short-cycl industri would remain
weak would fallout trade war uncertainti
dire commentari far come declar
slowdown intensifi like carri
ggg busi asiapac double-digit ceo warn
slowdown spread region mmm oper miss
sever pressur china auto
electron ten compani miss oper result posit
side surpass low expect reward
sizeabl relief ralli live safe monik beat
rais maintain neg sector view continu recommend
barbel weight defens stock waa
select cyclic ge
intern of daili
lundin petroleum lupe st dno dno ol dri well gladsheim hunt
htg trade updat confirm weak us complet activ
semi download samsung earn tomorrow
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
focu legaci vs new
take-away given weaker report provid last night key
comment suggest legaci system priorit look
earn week see high-tech product see better result versu legaci
system despit believ improv demand trend smartphones/
product micron vertic integr tsmc global foundri settl
 bank top bank trend fundament review
profit remain strong bank stock still own
growth robust capit posit strong credit qualiti continu expens
top bank exceed estim compar
pe buyer sentiment remain bearish ampl suppli earn season
us spot ethylen trade higher increas w/w per ihsm
us ethylen spot market activ week total pound
trade complet suppli level continu improv slowli overal spot price
move higher octob usgc wtd averag
price record increas septemb
us pe contract stabl week pe market quiet week
price supply/demand condit per ihsm na produc continu
seek contract price increas oct price contract negoti
final month-end
coverag list highlight earn season kick rais price target
na store growth link maintain outperform rate
continu volum price/cost improv link remain
posit continu abil gener focu harvest cash
investor link off-set weaker volum favor price link
rais price target ce product cash deploy link
maintain sector perform rate link pre-announce neg
earn weak lithium price weather impact link lower
ep guidanc link hun result street expect link
week host ceo ndr west coast
valu usd unless otherwis note
bottom line hit new high favor trade headlin
hope bottom industri economi report season
that better fear due abil c-suit manag
trade war/macro uncertainti cost cut help
willing equiti investor embrac theme resili recoveri
sector strongest weakest sell-sid revis recent seen best
reaction earn print remain neutral broader market
year-end reiter year-end target guard
mild pullback five reason posit problem return base
latest cftc data us equiti futur posit among asset manag
page valuat problem lurk valuat model
bump ceil past year page risk remain
bottom-up sell-sid forecast still track
adu realli approv clinic statist deep dive confer
follow last week surpris announc one ph iii aducanumab
studi read posit compani plan file bla receiv
numer question particularli statist element dataset
viabil plan better gaug adu regulatori commerci
potenti perform deep dive analysi clinic data incorpor
expert statistician perspect explor regulatori preced examin
upside/downsid potenti revenu fair valu conclud
pursu approv make sens odd still long estimate po despit
potenti substanti upsid opportun success like need
add studi support adu approv -- coupl ms sma risk reduc
floor -- keep us sidelin especi recent stock appreci
last week surpris announc one ph iii
aducanumab studi read posit compani plan file bla
receiv numer question
perform deep dive analysi clinic data incorpor
also explor regulatori preced examin upside/downsid
potenti aducanumab revenu fair valu share
host confer call tue oct et discuss
slide contain report depth
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict capit
market may restrict publish research report time time due regulatori restrict and/ intern complianc polici case
latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject compani
capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri busi
secur broker dealer jurisdict full extent permit law neither capit market affili person accept
liabil whatsoev direct indirect consequenti loss aris connect use report inform contain herein
matter contain document may reproduc copi mean without prior written consent capit market instanc
addit inform avail request
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
